GSK Investigational Site

Valenciennes 59322

0 studies enrolling now · 8 studies all time

What they study most

Acute Coronary Syndrome, Diabetes Mellitus, Type 2, Lung Cancer, Non-Small Cell, Nasal Polyps, Neoplasms, Breast, Neoplasms, Head and Neck, Severe Acute Respiratory Syndrome

Studies at this site

• Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps — Completed
• Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) — Stopped early
• Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease — Completed
• Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early
• Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus — Completed
• The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial — Completed
• A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) — Completed
• Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer — Completed